Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/infdis/175.1.231 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Romiplostim Reduces Platelet Transfusion Needs in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.
Cureus
December 2024
Department of Clinical Hematology and Bone Marrow Transplant (BMT), Command Hospital, Lucknow, IND.
Background: There is no standard treatment to accelerate recovery from melphalan-induced thrombocytopenia in multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT). Romiplostim, a thrombopoietin receptor agonist, has been developed to upregulate platelet production.
Objective: This study aimed to assess the efficacy and safety of romiplostim in reducing platelet transfusions post-ASCT in MM patients.
High paracrine activity of hADSCs cartilage microtissues inhibits extracellular matrix degradation and promotes cartilage regeneration.
Mater Today Bio
February 2025
Institute of Orthopedics, The Fourth Medical Center of Chinese PLA General Hospital, Beijing Key Lab of Regenerative Medicine in Orthopedics, Key Laboratory of Musculoskeletal Trauma & War Injuries PLA, No. 51 Fucheng Road, Beijing, 100048, PR China.
Due to its unique structure, articular cartilage has limited self-repair capacity. Microtissues are tiny tissue clusters that can mimic the function of target organs or tissues. Using cells alone for microtissue construction often results in the formation of necrotic cores.
View Article and Find Full Text PDFManagement of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report.
J Med Case Rep
January 2025
Director of Hospital Pharmacy, Santa Croce e Carle Hospital, Cuneo, Italy.
Background: Mantle cell lymphoma is a diverse B-cell lymphoma with varying clinical behaviors. Treating relapsed or refractory mantle cell lymphoma is challenging, with Bruton's tyrosine kinase inhibitors proving effective but not curative. Post-Bruton's tyrosine kinase inhibitor failure, the prognosis remains unfavorable.
View Article and Find Full Text PDFEfficacy of Autologous Cortico-Cancellous Bone Graft and Platelet-Rich Plasma with or without Bio-Oss in Bone Regeneration for Unilateral Alveolar Cleft Defects: A Randomized Controlled Trial.
J Stomatol Oral Maxillofac Surg
January 2025
Department of Oral and Maxillofacial Surgery, Vishnu Dental College, Bhimavaram, India. Electronic address:
Introduction: Alveolar cleft grafting is crucial in cleft lip and palate rehabilitation, promoting maxillary continuity and facilitating dental development. While autologous bone grafts are the gold standard, combining them with platelet-rich plasma (PRP) and xenografts like Bio-Oss has the potential to enhance bone regeneration and long-term stability. This study aimed to evaluate the synergistic effects of combining autologous cortico-cancellous bone grafts, PRP, and Bio-Oss in alveolar cleft repair.
View Article and Find Full Text PDFA Prospective, Open-Label, Randomized, Comparative, Investigator-Initiated Study to Evaluate the Safety and Effectiveness of Autologous Growth Factor Concentrate Using the Healrex Therapy Kit With Standard Wound Care in Lower-Extremity Diabetic Ulcer.
Cureus
December 2024
Business Development Hospitals, Wockhardt Hospitals Ltd., Mumbai, IND.
Background and objectives The persistent nature of diabetic foot ulcers (DFUs) is mainly attributable to compromised wound healing mechanisms, which are aggravated due to poor blood flow, neuropathy, and infection. Growth factors have become essential agents in the treatment of DFUs, serving as primary mediators that enhance wound healing through the stimulation of cell proliferation, migration, and angiogenesis. This prospective open-label, randomised, comparative, multi-centre, investigator-initiated study compared the safety and effectiveness of adjuvant therapy with topical application of autologous growth factor concentrate (AGFC) using the Healrex therapy kit (Wockhardt, India) versus standard of care (SoC) in DFUs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!